Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC and Evgen Pharma to explore treatment for osteoarthritis
Researchers will investigate the potential of the drug SFX-01 as a treatment for osteoarthritis.
Work will build on a previous collaboration

The RVC and Evgen pharma have secured funding from the Biotechnology and Biological Sciences Research Council (BBSRC) for a four-year PhD studentship focused on investigating treatment for osteoarthritis.

The Industrial Co-operative Awards in Science & Technology (CASE) PhD Studentship will allow researchers to investigate the potential of the drug SFX-01 as a treatment for the disease, which affects almost 9 million people across the UK.

The work will build on a previous collaboration, which showed that mice with spontaneously-arising osteoarthritis demonstrated significantly improved bone architecture and preservation of normal movement following three months of SFX-01 treatment.

Professor Andrew Pitsillides, who led the study, said: “Myself and my colleagues Drs Isabel Orriss and Behzad Javaheri in the RVC’s Skeletal Biology Group are very excited by the prospect of working with Evgen Pharma to identify the cellular and molecular targets by which SFX-01 exerts its beneficial actions in osteoarthritis.”

Evgen Pharma is a clinical stage drug development company that focuses on the treatment of cancer and neurological conditions.

CEO Dr Stephen Franklin commented: “As a Company, we remain focused on the delivery of our current Company sponsored clinical trials and our strategic focus is in cancer and neurology. 

“We will, however, provide SFX-01 to a limited number of world leading academics and clinical groups that wish to investigate SFX-01 in alternative therapeutic areas if they can demonstrate a robust clinical plan, source their own non-dilutive grant funding and we retain commercialisation rights.

“We, and the RVC, are delighted that the BBSRC is funding this programme and it is another step towards the possibility of a future, grant funded, clinical trial on SFX-01 in osteoarthritis”. 

Become a member or log in to add this story to your CPD history

Vets save premature penguin chick

News Story 1
 Vets have saved a tiny Humboldt penguin chick after her egg was accidentally broken by her parents. Keepers at ZSL London Zoo were shocked to find the chick, named Rainbow, still alive and rushed her straight to the Zoo’s on-site veterinary clinic.

It was a little way to go until the chick should have hatched, so the process was touch and go. Vets removed bits of shell from around the chick with tweezers until she could be lifted out and placed in a makeshift nest.

Rainbow is now in a custom-built incubation room where she spends her days cuddled up to a toy penguin. Keepers will hand-fed Rainbow for the next 10 weeks until she is healthy enough to move to the penguin nursery.  

Click here for more...
News Shorts
BVA infographic to help shoppers understand farm assurance schemes

An infographic to help members of the public understand farm assurance schemes has been produced by the BVA. The infographic outlines BVA’s priorities for animal welfare and shows whether or not the schemes address these priorities in their standards.

BVA president John Fishwick said: “The infographic is not intended to be a league table but to allow people to understand what aspects of animal health and welfare are addressed by assurance schemes so that they can decide which scheme best aligns with their own individual preferences and priorities."